Kallistatin Levels in Polycystic Ovary Syndrome: A Novel Biomarker for Insulin Resistance and Metabolic Dysregulation: A Case-Control Study
,
Abstract
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder among women of reproductive age. Characterized by a heterogeneous constellation of hormonal, metabolic, and reproductive abnormalities, PCOS manifests through three cardinal features: oligo‑ or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. This disorder is associated with major metabolic consequences, such as an increased risk of developing metabolic syndrome. This study aimed to investigate the potential role of kallistatin as a biomarker for PCOS, focusing on its association with insulin resistance (IR) and its regulatory function in inflammation. In this study, 30 healthy controls were matched with 60 patients with PCOS based on BMI, height, weight, and age. The study was carried out in the Fertility Center, Department of Gynecology, at Al‑Zahraa Teaching Hospital and Al‑Sadr Medical City from January 10, 2024, to January 24, 2025. Kallistatin levels were measured using ELISA, and insulin resistance was determined using the HOMA‑IR index. The study compared metabolic and hormonal parameters between 60 PCOS patients and 30 healthy controls. Significant differences (P<0.001) were observed: PCOS patients exhibited elevated insulin levels (14.91±3.01 vs. 8.22±2.47) and HOMA‑IR (3.77±1.01 vs. 1.74±0.52), along with reduced kallistatin levels (2.34±0.76 vs. 5.59±1.58 ng/ml). A notable correlation was found between kallistatin levels and both insulin resistance and lipid profiles. This study provides compelling evidence for the potential role of kallistatin as a biomarker for PCOS. The findings revealed significantly lower kallistatin levels in PCOS patients than in healthy controls, suggesting its potential utility in the diagnosis and prognosis of the condition.
2. Elhddad A. Insulin resistance in obese and non‑obese PCOS patients using homeostasis model assessment insulin resistant: a comparison study. IJFMR 2023;5:1-12.
3. Moreira-Gomes P, Azevedo F, Lisboa C. Polycystic ovary syndrome: a dermatologic approach. Port J Dermatol Venereol 2024;82.
4. Malini NA, Roy GK. Influence of insulin on LH, testosterone and SHBG in various PCOS categories based on the mode of secretion of LH in relation to FSH levels. Acta Endocrinol (Buchar) 2021;17:313-8.
5. Hmoud TR, Jawad MM, Alredha RDA. Hormonal profiles and the diagnostic utility of serum dihydrotestosterone in polycystic ovary syndrome: a comparative case-control study. Eur J Transl Clin Med 2025;8:17-24.
6. Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 2010;122:42-52.
7. Alredha RDA, Haddawi KH, Al-Hayali WR, Yaseen BR. Evaluation of hormonal and adipokine biomarkers in the diagnosis of polycystic ovary syndrome: a case-control study. Eur J Clin Exp Med 2025;23:324-33.
8. Virtanen N, Pesonen E, Saarela U, Hurskainen E, Arffman RK, Koivunen P, et al. Association of hemoglobin levels with metabolic traits in women with PCOS. Acta Obstet Gynecol Scand 2025. (Epub ahead of print.)
9. Chao J, Bledsoe G, Chao L. Protective role of kallistatin in vascular and organ injury. Hypertension 2016;68:533-41.
10. Chao J, Li P, Chao L. Kallistatin: double-edged role in angiogenesis, apoptosis and oxidative stress. Biol Chem 2017;398:1309-17.
11. Wang G, Zou J, Yu X, Yin S, Tang C. The antiatherogenic function of kallistatin and its potential mechanism. Acta Biochim Biophys Sin (Shanghai) 2020;52:583-9.
12. Chang S, Dunaif A. Diagnosis of polycystic ovary syndrome: which criteria to use and when? Endocrinol Metab Clin North Am 2021;50:11-23.
13. Alkheyr Z, Murad M, Das P, Aljenaee K, Kamel C, Hajji SA, et al. Self-esteem and body image satisfaction in women with PCOS in the Middle East: cross-sectional social media study. PLoS One 2024;19:e0301707.
14. Spinelli A, Buoncristiano M, Nardone P, Starc G, Hejgaard T, Júlíusson PB, et al. Thinness, overweight, and obesity in 6–9-year-old children from 36 countries: the WHO European Childhood Obesity Surveillance Initiative—COSI 2015–2017. Obes Rev 2021;22:e13214.
15. Farhadi-Azar M, Behboudi-Gandevani S, Rahmati M, Mahboobifard F, Khalili Pouya E, Ramezani Tehrani F, et al. The prevalence of polycystic ovary syndrome, its phenotypes and cardio‑metabolic features in a community sample of Iranian population: Tehran lipid and glucose study. Front Endocrinol (Lausanne) 2022;13:825528.
16. Mohammadi M. Oxidative stress and polycystic ovary syndrome: a brief review. Int J Prev Med 2019;10:86.
17. Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update 2013;19:268-88.
18. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010;8:41.
19. Liu S, Zhao X, Meng Q, Li B. Screening of potential biomarkers for polycystic ovary syndrome and identification of expression and immune characteristics. PLoS One 2023;18:e0293447.
20. Ding H, Zhang J, Zhang F, Zhang S, Chen X, Liang W, et al. Resistance to insulin and elevated androgen level: a major cause of polycystic ovary syndrome. Front Endocrinol (Lausanne) 2021;12:741764.
21. Yang J, Chen C. Hormonal changes in PCOS. J Endocrinol 2024;261.
22. Rudnicka E, Suchta K, Grymowicz M, Calik‑Ksepka A, Smolarczyk K, Duszewska AM, et al. Chronic low‑grade inflammation in pathogenesis of PCOS. Int J Mol Sci 2021;22:3789.
23. Rehman K, Akash MSH. Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? J Biomed Sci 2016;23:87.
24. Calan M, Guler A, Alarslan P, Bicer M, Imamoglu C, Yuksel A, et al. Association of kallistatin with carotid intima-media thickness in women with polycystic ovary syndrome. Minerva Endocrinol 2017;43:236-45.
25. Yurtkal A, Canday M. Kallistatin as a potential biomarker in polycystic ovary syndrome: a prospective cohort study. Diagnostics (Basel) 2024;14:1553.
26. Sandforth L, Brachs S, Reinke J, Willmes D, Sancar G, Seigner J, et al. Role of human kallistatin in glucose and energy homeostasis in mice. Mol Metab 2024;82:101905.
27. Dey R, Bhattacharya K, Basak AK, Paul N, Bandyopadhyay R, Chaudhuri GR, et al. Inflammatory perspectives of polycystic ovary syndrome: role of specific mediators and markers. Middle East Fertil Soc J 2023;28:33.
| Files | ||
| Issue | Vol 64 No 4 (2026) | |
| Section | Original Articles | |
| Keywords | ||
| Kallistatin level Polycystic ovary syndrome (PCOS) Insulin resistance (IR) Lipids profile | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
